Novel hormone analogues for appetite suppression
Thiakis was founded in 2004 to develop novel analogues of naturally occurring hormones for the treatment of obesity and co-morbidities based on the research of Professor Steve Bloom.
CEO John Burt
Advent invested in the Series A in 2006. Thiakis was acquired by Wyeth in 2008 in a transaction worth up to $150m.
Wyeth Pharmaceuticals acquires Thiakis in a transaction worth up to £100m
Press Release. London, December 18, 2008. Advent Venture Partners (‘Advent Ventures’) today announces the sale of one of its portfolio companies, Thiakis, to Wyeth Pharmaceuticals, a division of Wyeth…Read More